The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients
- PMID: 1389940
- PMCID: PMC1381360
- DOI: 10.1111/j.1365-2125.1992.tb04097.x
The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients
Abstract
Eleven HIV-infected men participated in a randomized, two-treatment, two-period crossover study to determine the effect of a 25 g protein meal on zidovudine pharmacokinetics. On two separate occasions, 1 week apart, each patient received 200 mg zidovudine in a fasting state or immediately following the protein meal. A protein meal significantly decreased Cmax [532 (228 s.d.) vs 802 (452 s.d.) ng ml-1, P = 0.004] and increased mean residence time (138 (26 s.d.) vs 114 (26 s.d.) min, corrected for lag times, P = 0.001). However, AUC, tmax, terminal half-life and renal clearance were not significantly altered (P greater than 0.05). The power to detect a 20% change in AUC was 98% at the 5% significance level. In contrast to fat-containing foods, protein-based meals may not alter the extent of zidovudine absorption.
Similar articles
-
Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients.Br J Clin Pharmacol. 1993 Aug;36(2):128-31. doi: 10.1111/j.1365-2125.1993.tb04208.x. Br J Clin Pharmacol. 1993. PMID: 8398581 Free PMC article.
-
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.Clin Pharmacokinet. 1996 Apr;30(4):314-27. doi: 10.2165/00003088-199630040-00004. Clin Pharmacokinet. 1996. PMID: 8983861 Review.
-
Evaluation of the in vivo effect of naproxen on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus.Clin Pharmacol Ther. 1992 Nov;52(5):464-70. doi: 10.1038/clpt.1992.173. Clin Pharmacol Ther. 1992. PMID: 1424420 Clinical Trial.
-
Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients.Br J Clin Pharmacol. 1999 Aug;48(2):168-79. doi: 10.1046/j.1365-2125.1999.00987.x. Br J Clin Pharmacol. 1999. PMID: 10417493 Free PMC article. Clinical Trial.
-
Clinical pharmacokinetics of zidovudine. An update.Clin Pharmacokinet. 1996 Apr;30(4):251-62. doi: 10.2165/00003088-199630040-00001. Clin Pharmacokinet. 1996. PMID: 8983858 Review.
Cited by
-
Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.Antimicrob Agents Chemother. 1998 Sep;42(9):2295-8. doi: 10.1128/AAC.42.9.2295. Antimicrob Agents Chemother. 1998. PMID: 9736552 Free PMC article. Clinical Trial.
-
Pharmacokinetics of zidovudine after the initial single dose and during chronic-dose therapy in HIV-infected patients.Br J Clin Pharmacol. 1993 Aug;36(2):128-31. doi: 10.1111/j.1365-2125.1993.tb04208.x. Br J Clin Pharmacol. 1993. PMID: 8398581 Free PMC article.
-
Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.Drugs. 1993 Sep;46(3):515-578. doi: 10.2165/00003495-199346030-00010. Drugs. 1993. PMID: 7693435 Review.
-
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.Clin Pharmacokinet. 1996 Apr;30(4):314-27. doi: 10.2165/00003088-199630040-00004. Clin Pharmacokinet. 1996. PMID: 8983861 Review.
-
Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.Pharm World Sci. 1995 Mar 24;17(2):25-30. doi: 10.1007/BF01875051. Pharm World Sci. 1995. PMID: 7795555 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical